Showing 1 to 1 of 1 results
cnn.com
🌐 85% Global Worthiness
Chinese Biotech Drug Outperforms Keytruda in Clinical Trials
Akeso's new lung cancer drug, Ivonescimab, outperformed Merck's Keytruda in Chinese clinical trials, extending progression-free survival; this success, coupled with increased licensing deals, highlights the rise of China's pharmaceutical innovation, though challenges in consumer trust and regulatory...
Chinese Biotech Drug Outperforms Keytruda in Clinical Trials
Akeso's new lung cancer drug, Ivonescimab, outperformed Merck's Keytruda in Chinese clinical trials, extending progression-free survival; this success, coupled with increased licensing deals, highlights the rise of China's pharmaceutical innovation, though challenges in consumer trust and regulatory...
Progress
48% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results